Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomasM J Glantz, H Choy, C M Kearns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancerD I Jodrell, L M Reyno, R Sridhara, et al.
Journal of the National Cancer Institute|August 18, 1993
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B studyS M Lichtman, M J Ratain, D A Van Echo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumorsA Patnaik, E Warner, M Michael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignanciesP M Fracasso, P Westervelt, C L Fears, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565A P Venook, M J Egorin, G L Rosner, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2001
Phase I study of docetaxel and topotecan in patients with solid tumorsK H Tkaczuk, W C Zamboni, N S Tait, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Seminars in Oncology|October 1, 1994
Modeling toxicity and response in carboplatin-based combination chemotherapyM J Egorin, L M Reyno, R M Canetta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomasM J Glantz, H Choy, C M Kearns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancerD I Jodrell, L M Reyno, R Sridhara, et al.
Journal of the National Cancer Institute|August 18, 1993
Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B studyS M Lichtman, M J Ratain, D A Van Echo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumorsA Patnaik, E Warner, M Michael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2000
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignanciesP M Fracasso, P Westervelt, C L Fears, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565A P Venook, M J Egorin, G L Rosner, et al.
American Journal of Respiratory and Critical Care Medicine|October 6, 1997
Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study GroupR Hafner, J A Cohn, D J Wright, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2001
Phase I study of docetaxel and topotecan in patients with solid tumorsK H Tkaczuk, W C Zamboni, N S Tait, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Pageof 16